Answers are grounded in this paper and cite their sources.
Three new 2,6-disubstituted thiosemicarbazone derivatives of pyridine, namely, 2-{amino[6-(pyrrolidin-1-yl)pyridin-2-yl]methylidene}- N , N -dimethylhydrazine-1-carbothioamide, C 13 H 20 N 6 S, 2-{amino[6-(piperidin-1-yl)pyridin-2-yl]methylidene}- N , N -dimethylhydrazine-1-carbothioamide, C 14 H 22 N 6 S, and 2-[amino(6-phenoxypyridin-2-yl)methylidene]- N , N -dimethylhydrazine-1-carbothioamide monohydrate, C 15 H 17 N 5 OS·H 2 O, have been synthesized and characterized by NMR spectroscopy and low-temperature single-crystal X-ray diffraction. In addition, their antibacterial and anti-yeast activities have been determined. The ability of the tested compounds to inhibit bacterial growth was comparable to vancomycin as a reference drug. Compared to isoniazid (MIC 0.125 and 8 µg ml −1 ), the compounds showed the ability to inhibit the growth of Mycobacterium tuberculosis to a moderate degree for the standard strain and at the same level or higher (MIC 4–8 µg ml −1 ) for the resistant strain. All three compounds adopt the zwitterionic form in the crystal structure regardless of the presence or absence of solvent molecules.
No takes yet. Share an insight, caveat, or question.
Ziembicka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: